Dr Reddy’s Laboratories (DRL) recently launched its bioequivalent generic version of Amoxil (Amoxicillin) tablets, capsules, and oral suspension in the US market on September 17. Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg), and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) are approved by the United States Food and Drug Administration (US FDA). The Amoxil brand and generic tablets (875 mg) has US sales of approximately $22.2 million, while capsules had US sales of approximately $67.2 million, and oral suspension clocked US sales of approximately $89.5 million, all for the most recent 12 months ending June 2012 according to IMS Health.
EP News Bureau